The financials
Biogen by the numbers
Biogen (BIIB) reported revenue of $2.48B in Q1 2026 (quarter ended March 31, 2026), up 1.9% from the same quarter a year earlier. That came with a gross margin of 73% and net income of $320M (13% of revenue). For the full year FY2025, revenue was $9.89B (+2.2% year on year) and net income $1.29B. Its largest product in 2026-Q1 was Royalty Attributed To OCREVUS at $317M, 13% of the disclosed total, just ahead of Product And Service Other at 10%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $2.48B | $2.43B | +1.9% |
| Gross profit | $1.82B | $1.80B | +0.8% |
| Operating income | $378M | $311M | +21% |
| Net income | $320M | $241M | +33% |
| Diluted EPS | $2.15 | $1.64 | +31% |
| Product | Revenue | Share |
|---|---|---|
| Royalty Attributed To OCREVUS | $317M | 13% |
| Product And Service Other | $247M | 10% |
| Tysabri Product | $242M | 10% |
| Contract Manufacturing And Other | $237M | 10% |
| Rare Disease Product | $225M | 9.5% |
| Fumarate | $185M | 7.8% |
| VUMERITY | $153M | 6.5% |
| SPINRAZA | $142M | 6.0% |
| Interferon | $133M | 5.6% |
| AVONEX | $109M | 4.6% |
| SKYCLARYS | $72M | 3.0% |
| Alzheimers Collaboration | $60M | 2.5% |
| LEQEMBI Collaboration | $60M | 2.5% |
| Other Products | $55M | 2.3% |
| ZURZUVAE | $55M | 2.3% |
| TECFIDERA | $31M | 1.3% |
| PLEGRIDY | $24M | 1.0% |
| QALSODY | $11M | 0.4% |
| Royalty | $9.7M | 0.4% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $2.37B (-1.3%)
ZURZUVAE grew +100% year on yearTOFIDENCE -100% year on year
Segment Latestquarter on quarteryear on year
- Royalty Attributed To OCREVUS$317.2M$317.2MQoQ -18%year on year +9.8%-18%+9.8%
- Product And Service Other$246.9M$246.9MQoQ +63%year on year -16%+63%-16%
- Tysabri Product$241.8M$241.8MQoQ -2.3%year on year +20%-2.3%+20%
- Contract Manufacturing And Other$237.2M$237.2MQoQ +68%year on year -16%+68%-16%
- Rare Disease Product$224.5M$224.5MQoQ -4.5%year on year -2.8%-4.5%-2.8%
- Fumarate$184.8M$184.8MQoQ -21%year on year +18%-21%+18%
- VUMERITY$153.4M$153.4MQoQ -19%year on year +31%-19%+31%
- SPINRAZA$142.2M$142.2MQoQ -7.2%year on year -7.9%-7.2%-7.9%
- Interferon$132.8M$132.8MQoQ -18%year on year +0.08%-18%+0.08%
- AVONEX$108.5M$108.5MQoQ -19%year on year -0.09%-19%-0.09%
- SKYCLARYS$71.8M$71.8MQoQ -3.8%year on year +3.9%-3.8%+3.9%
- Alzheimers Collaboration$59.5M$59.5MQoQ +39%year on year +80%+39%+80%
- LEQEMBI Collaboration$59.5M$59.5MQoQ +39%year on year +80%+39%+80%
- Other Products$55.3M$55.3MQoQ 0.00%year on year +97%0.00%+97%
- ZURZUVAE$55.3M$55.3MQoQ 0.00%year on year +100%0.00%+100%
- TECFIDERA$31.4M$31.4MQoQ -30%year on year -21%-30%-21%
- PLEGRIDY$24.3M$24.3MQoQ -13%year on year +0.83%-13%+0.83%
- QALSODY$10.5M$10.5MQoQ +44%year on year +40%+44%+40%
- Royalty$9.7M$9.7MQoQ 0.00%year on year -12%0.00%-12%
- BENEPALI$0.00$0.00QoQ -year on year ---
- BYOOVIZ$0.00$0.00QoQ -100%year on year -100%-100%-100%
- Biosimilars$0.00$0.00QoQ -100%year on year -100%-100%-100%
- FAMPYRA$0.00$0.00QoQ -year on year ---
- FLIXABI$0.00$0.00QoQ -year on year ---
- FUMADERM And ADUHELM$0.00$0.00QoQ -year on year -100%--100%
- IMRALDI$0.00$0.00QoQ -year on year ---
- TOFIDENCE$0.00$0.00QoQ -year on year -100%--100%
Drug Manufacturers - General
Ranks #12 of 16 by Smart Score